Introduction

Orthostatic hypotension, also known as postural hypotension, is a state of dizziness that is caused due to low blood pressure. This is commonly happen when a person stands up from a long sitting and feel dizziness. Orthostatic hypotension can be caused due to heart problems, dehydration, endocrine problems and nervous system disorders. Also, it has been found that nursing home elderly residents are more prone to OH than people who stay living in the community.

In OH, there is at least 10 mm Hg in diastolic blood pressure and 20 mm Hg fall in systolic blood pressure. Generally, OH last for few seconds to few minutes however, long lasting of OH is a sign of serious problem and one must consult with a doctor. Rate of hospitalization for OH is highly prevalent among geriatrics population.

The orthostatic hypotension disorder is mostly common in the elderly, teenagers and postpartum mothers. The key drivers that can boost the orthostatic hypotension market are increasing in the aging population with increase in the prevalence of diabetes and heart disorders along with availability of increasing number of treatments options.

Increasing adoption and integration of technologies in healthcare premises along with emergence of new entrants in the existing market is expected to further propel the demand for treatment of orthostatic hypotension worldwide. Though the market is poised to witness healthy growth during the forecast period, threat of side effects with the medicines is proving a major restraint to overall growth of the market.

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Get FREE Report Sample

Market Segmentation

by Drug type	Fludrocortisone Midodrine hydrochloride Droxidopa Pyridostigmine Indomethacin Caffeine Epoetin Oxilofrine potassium chloride NSAIDs ( Nonsteroidal anti-inflammatory drugs)
by Diagnostics test type	ECG Blood tests Stress test Echocardiogram
by end use type	Hospitals Diagnostic centers Clinics Ambulatory surgical centers
geographic region	North America Latin America Europe Asia Pacific Middle East & Africa

Availability of variety of antihypertensive agents for the treatment of orthostatic hypotension is expected to drive the global orthostatic hypotension treatment market. Innovative treatment and diagnostic options are expected to contribute in the growth of orthostatic hypotension market in the forecast period. Among the available drugs for treatment fludrocortisone is used widely to increase the amount of fluid containing in the blood which would contribute for the increased market share of orthostatic hypotension market.

North America dominates the global orthostatic hypotension market followed by Europe, Japan and Asia Pacific. The developing nations in Asia Pacific, Middle East and Africa hold huge potential for growth in the orthostatic hypotension market due to its affordable prices and number of clinical trials conducted in these regions. Also, over the period of time, there has been significant growth in terms of healthcare expenditure.

Liberalization of stringent regulatory policies along with high emphasis on FDI has led to significant investment in healthcare sectors in developing regions. This in turn, is expected to boost the healthcare market in developing regions especially Asia Pacific excluding Japan (APEJ).

Key players of orthostatic hypotension market are Mylan Inc, Upsher-Smith Laboratories, Chelsea Therapeutics, Amgen, F. Hoffman-La Roche. Apotex, Inc.